Amundi Pioneer Asset Management Inc. bought a new stake in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 189,899 shares of the biopharmaceutical company’s stock, valued at approximately $9,517,000. Amundi Pioneer Asset Management Inc. owned about 0.72% of Esperion Therapeutics at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Tower Research Capital LLC TRC raised its holdings in shares of Esperion Therapeutics by 69,371.4% during the second quarter. Tower Research Capital LLC TRC now owns 4,863 shares of the biopharmaceutical company’s stock valued at $225,000 after acquiring an additional 4,856 shares during the last quarter. Aperio Group LLC acquired a new position in shares of Esperion Therapeutics during the second quarter valued at approximately $249,000. SG Americas Securities LLC raised its holdings in shares of Esperion Therapeutics by 74.5% during the second quarter. SG Americas Securities LLC now owns 7,008 shares of the biopharmaceutical company’s stock valued at $324,000 after acquiring an additional 2,991 shares during the last quarter. Voya Investment Management LLC raised its holdings in shares of Esperion Therapeutics by 12.7% during the second quarter. Voya Investment Management LLC now owns 7,148 shares of the biopharmaceutical company’s stock valued at $331,000 after acquiring an additional 806 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY acquired a new position in shares of Esperion Therapeutics during the first quarter valued at approximately $385,000. 92.27% of the stock is owned by institutional investors and hedge funds.

A number of equities analysts have commented on ESPR shares. Northland Securities started coverage on Esperion Therapeutics in a report on Tuesday, August 29th. They set an “outperform” rating and a $72.00 target price for the company. Jefferies Group reissued a “buy” rating and set a $85.00 target price on shares of Esperion Therapeutics in a report on Monday, August 21st. Zacks Investment Research upgraded Esperion Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 23rd. Cowen initiated coverage on Esperion Therapeutics in a research report on Thursday, September 7th. They issued an “outperform” rating and a $64.00 price target for the company. Finally, BidaskClub lowered Esperion Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 4th. Six research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $58.92.

Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) opened at $61.51 on Friday. Esperion Therapeutics, Inc. has a 52-week low of $10.30 and a 52-week high of $61.70.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.79) by ($0.07). During the same quarter last year, the firm posted ($0.77) earnings per share. sell-side analysts forecast that Esperion Therapeutics, Inc. will post -7.21 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This article was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another website, it was stolen and reposted in violation of United States and international trademark and copyright laws. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/12/01/amundi-pioneer-asset-management-inc-buys-shares-of-189899-esperion-therapeutics-inc-espr.html.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.